Sangamo Therapeutics Inc (SGMO) concluded trading on Wednesday at a closing price of $0.55, with 20.11 million shares of worth about $11.06 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -51.73% during that period and on July 23, 2025 the price saw a gain of about 13.69%. Currently the company’s common shares owned by public are about 245.40M shares, out of which, 237.64M shares are available for trading.
Stock saw a price change of 13.34% in past 5 days and over the past one month there was a price change of 26.27%. Year-to-date (YTD), SGMO shares are showing a performance of 37.37% which decreased to -46.52% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.39 but also hit the highest price of $3.18 during that period. The average intraday trading volume for Sangamo Therapeutics Inc shares is 4.88 million. The stock is currently trading 5.56% above its 20-day simple moving average (SMA20), while that difference is up 8.68% for SMA50 and it goes to -51.25% lower than SMA200.
Sangamo Therapeutics Inc (NASDAQ: SGMO) currently have 245.40M outstanding shares and institutions hold larger chunk of about 21.97% of that.
The stock has a current market capitalization of $133.86M and its 3Y-monthly beta is at 1.19. It has posted earnings per share of -$0.38 in the same period. It has Quick Ratio of 0.76 while making debt-to-equity ratio of 5.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SGMO, volatility over the week remained 8.05% while standing at 8.63% over the month.
Stock’s fiscal year EPS is expected to rise by 25.97% while it is estimated to increase by 6.79% in next year. EPS is likely to grow at an annualized rate of 24.16% for next 5-years, compared to annual growth of 10.57% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Truist on December 13, 2024 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by H.C. Wainwright stated Sangamo Therapeutics Inc (SGMO) stock as a Buy in their note to investors on December 10, 2024, suggesting a price target of $10 for the stock. On November 03, 2023, RBC Capital Mkts Downgrade their recommendations, while on April 28, 2023, BofA Securities Downgrade their ratings for the stock with a price target of $1.50. Stock get an Outperform rating from Wedbush on February 27, 2023.
